ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IPHA Innate Pharma SA

2.45
0.05 (2.08%)
Last Updated: 10:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Innate Pharma SA IPHA NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.05 2.08% 2.45 10:30:00
Open Price Low Price High Price Close Price Previous Close
2.41 2.41 2.46 2.40
more quote information »

Recent News

Date Time Source Heading
4/15/202400:00BWInnate Pharma annonce la progression de l’essai clinique..
4/10/202400:00BWInnate Pharma Presents at AACR 2024 Preclinical Efficacy of..
4/09/202400:00BWInnate Pharma Announces Its Participation in Upcoming..
4/05/202402:34BWInnate Pharma publie son Document D’enregistrement Universel..
3/21/202401:00BWInnate Pharma Reports Full Year 2023 Financial Results and..
3/19/202401:00BWInnate Pharma annonce sa participation à une prochaine..
3/14/202401:00BWInnate Pharma Announces Conference Call and Webcast for Full..
3/06/202400:00BWInnate Pharma présentera des données précliniques concernant..
2/21/202400:00BWInnate Pharma annonce sa participation a une prochaine..
1/16/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
1/12/202405:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/12/202400:00BWNumber of Shares and Voting Rights of Innate Pharma as of..
1/05/202405:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/04/202405:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/04/202405:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/04/202400:00BWInnate Pharma Announces U.S. FDA Lifts Partial Clinical Hold..
1/03/202423:59BWInnate Pharma renforce son équipe de direction et nomme deux..
12/20/202315:45EDGAR2Form F-3 - Registration statement by foreign private issuers
12/20/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/19/202306:28DJNInnate Pharma Shares Rise after Sanofi Exercises Licensing..
12/19/202300:00BWInnate Pharma annonce la licence d’un quatrième NK Cell..
12/18/202300:00BWInnate Pharma Announces Leadership Change
12/11/202300:00BWInnate Pharma partage les résultats d’efficacité et de..
12/10/202300:00BWInnate Pharma présente les résultats positifs de l’étude de..
11/27/202300:00BWInnate Pharma organise une conférence virtuelle avec un..
11/14/202300:00BWInnate Pharma présente ses résultats financiers au troisième..
11/07/202300:00BWInnate Pharma organise une conférence téléphonique pour ses..
11/03/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/03/202301:00BWInnate Pharma annonce la présentation de nouvelles données..
10/27/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/27/202300:00BWInnate Pharma annonce sa participation à de prochaines..
10/19/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/19/202300:00BWInnate Pharma 2024 Financial Calendar
10/16/202300:00BWInnate Pharma annonce les abstracts sélectionnés au congrès..
10/09/202300:00BWNouveau nombre d’actions et de droits de vote d’Innate..
10/05/202307:14DJNInnate Pharma Shares Fall Premarket on FDA Partial Study..
10/05/202300:00BWInnate Pharma annonce une mise à jour sur le programme..
9/22/202300:00BWInnate Pharma Announces Encore Presentation of Interim..
9/14/202305:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
9/14/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
9/14/202300:00BWInnate Pharma Reports First Half 2023 Financial Results and..
8/29/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/29/202300:00BWInnate Pharma annonce sa participation à de prochaines..
8/10/202300:00BWProchain rendez-vous investisseurs d'Innate Pharma
7/11/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/11/202300:00BWPremier patient traité dans l'essai clinique de Phase 1/2..
7/07/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/07/202300:00BWNouveau nombre d’actions et de droits de vote d’Innate..
6/26/202300:00BWInnate Pharma : Traitement du premier patient dans l’essai..
6/16/202300:00BWInnate Pharma Highlights Increased Lacutamab Clinical..

Your Recent History

Delayed Upgrade Clock